Evidence map›Paper›PMID 42133627›Full record

ArticlePLOS global public health2026

Practitioner's perspectives on access to Rabies Post-Exposure Prophylaxis in Tanzania: A mixed-methods and theoretically-informed study to inform policy and practice.

Kennedy Lushasi, Eleanor M Rees, Camille Barker, Nai Rui Chng, Ally Halfan, Christian Tetteh Duamor, Elaine Ferguson, Felix Lankester, Husna Hoffu, Joel Changalucha and 3 more

Abstract read
In one paragraph

Article in PLOS global public health, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed.

  1. Article
  2. Article
  3. Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

13 authors.

Kennedy LushasiEnvironmental Health and Ecological Sciences, Ifakara Health Institute, Dar es Salaam, Tanzania.ORCID https://orcid.org/0000-0002-2060-4202
Eleanor M ReesSchool of Biodiversity, One Health & Veterinary Medicine, College of Medical, Veterinary & Life Sciences, University of Glasgow, Glasgow, United Kingdom.
Camille BarkerSchool of Biodiversity, One Health & Veterinary Medicine, College of Medical, Veterinary & Life Sciences, University of Glasgow, Glasgow, United Kingdom.
Nai Rui ChngSchool of Biodiversity, One Health & Veterinary Medicine, College of Medical, Veterinary & Life Sciences, University of Glasgow, Glasgow, United Kingdom.
Ally HalfanEnvironmental Health and Ecological Sciences, Ifakara Health Institute, Dar es Salaam, Tanzania.
Christian Tetteh DuamorEnvironmental Health and Ecological Sciences, Ifakara Health Institute, Dar es Salaam, Tanzania.ORCID https://orcid.org/0000-0001-8930-9060
Elaine FergusonSchool of Biodiversity, One Health & Veterinary Medicine, College of Medical, Veterinary & Life Sciences, University of Glasgow, Glasgow, United Kingdom.
Felix LankesterPaul G. Allen School for Global Animal Health, Washington State University, Pullman, Washington, United States of America.
Husna HoffuEnvironmental Health and Ecological Sciences, Ifakara Health Institute, Dar es Salaam, Tanzania.
Joel ChangaluchaEnvironmental Health and Ecological Sciences, Ifakara Health Institute, Dar es Salaam, Tanzania.
Lwitiko SikanaEnvironmental Health and Ecological Sciences, Ifakara Health Institute, Dar es Salaam, Tanzania.ORCID https://orcid.org/0000-0003-4212-2455
Mikolaj KundegorskiSchool of Biodiversity, One Health & Veterinary Medicine, College of Medical, Veterinary & Life Sciences, University of Glasgow, Glasgow, United Kingdom.ORCID https://orcid.org/0000-0002-0982-9371
Katie HampsonSchool of Biodiversity, One Health & Veterinary Medicine, College of Medical, Veterinary & Life Sciences, University of Glasgow, Glasgow, United Kingdom.

Funding

Eliminating human rabies: impact of enhanced vaccination coverageR01AI141712 · NIAID · WASHINGTON STATE UNIVERSITY · PI LANKESTER, FELIX · 2019 to 2023
$2.3M
NIAID NIH HHS R01 AI141712
6 · The paper itself

Abstract

Rabies remains a preventable yet fatal disease that continues to claim lives in low- and middle-income countries due to barriers in accessing post-exposure prophylaxis (PEP). With Gavi, the Vaccine Alliance, now supporting PEP provision in rabies-endemic countries, understanding access barriers is critical. We used mixed-methods to synthesise quantitative data on bite patients (>10,000) captured through an Integrated Bite Case Management platform across four regions of Tanzania, with qualitative data from hotline calls and peer-support chat established among health and veterinary workers from 2018 to 2024. We applied an expanded healthcare access framework comprising six dimensions: availability, accessibility, affordability, accommodation, acceptability, and appropriateness to guide our analyses and assess barriers and facilitators to PEP delivery and uptake in these regions. We identified interconnected barriers to PEP access including recurrent vaccine stockouts (up to 9.2% regionally); long travel distances that were greater for rural patients (on average: 34 vs 13 km for urban patients) who represented the majority at risk; and unaffordable direct and indirect costs leading bite victims to either not start or abandon PEP, incur risky delays or default to traditional remedies. Incorrect bite patient management, including misuse of biologicals sold at unregulated private pharmacies led to preventable deaths, while insufficient vaccination supplies and inadequate service hours, increased risks and costs to patients. Despite these gaps, peer-support mechanisms improved patient management and real-time problem-solving. PEP delivery in Tanzania is undermined by systemic barriers across all access dimensions. Addressing these requires decentralizing vaccine delivery to prioritized accessible facilities, ensuring reliable stock and supplies for intradermal administration, reducing patient costs, strengthening health worker capacity through training and support, and regulating private providers. Lessons from Tanzania highlight the need for context-sensitive, equity-focused strategies to maximize the impact of Gavi's investment and accelerate progress toward Zero by 30.

Identifiers

PMID42133627
PMCPMC13175354

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.